Shanghai Henlius Biotech adopts amended articles of association

Shanghai Henlius Biotech, Inc. (HKEX:2696) announced today the adoption of amended and restated articles of association, approved at a general meeting held on May 8, 2025. The amendments reflect the company’s commitment to aligning its operational structure with current regulatory standards, the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other relevant provisions. The company's registered capital is set at RMB543,494,853 divided into 543,494,853 shares, with a par value of RMB1 each. The initial public offering of overseas-listed foreign shares, the Company's share capital consists of 364,189,618 domestic shares, 15,876,694 unlisted foreign shares and 163,428,541 overseas-listed foreign shares. The updated articles address shareholder rights, board responsibilities, and operational procedures, intending to streamline decision-making processes and enhance transparency.